Comparison of HTLV-I Proviral Load in Adult T Cell Leukemia/Lymphoma (ATL), HTLV-I-Associated Myelopathy (HAM-TSP) and Healthy Carriers

Objective(s): Human T Lymphocyte Virus Type one (HTLV-I) is a retrovirus that infects about 10-20 million people worldwide. Khorasan province in Iran is an endemic area. The majority of HTLV-I-infected individuals sustain healthy carriers but small proportion of infected population developed two progressive diseases: HAM/TSP and ATL. The proviral load could be a virological marker for disease monitoring, therefore in the present study HTLV-I proviral load has been evaluated in ATL and compared to HAM/TSP and healthy carriers. Materials and Methods: In this case series study, 47 HTLV-I infected individuals including 13 ATL, 23 HAM/TSP and 11 asymptomatic subjects were studied. Peripheral blood mononuclear cells (PBMCs) were investigated for presence of HTLV-I DNA provirus by PCR using LTR and Tax fragments. Then in infected subjects, HTLV-I proviral load was measured using real time PCR TaqMan method. Results: The average age of patients in ATL was 52±8, in HAM/TSP 45.52±15.17 and in carrier’s 38.65±14.9 years which differences were not statistically significant. The analysis of data showed a significant difference in mean WBC among study groups (ATL vs HAM/TSP and carriers P=0.0001). Moreover, mean HTLV-I proviral load was 11967.2 ± 5078, 409 ± 71.3 and 373.6 ± 143.3 in ATL, HAM/TSP and Healthy Carriers, respectively. The highest HTLV-I proviral load was measured in ATL group that had a significant correlation with WBC count (R=0.495, P=0.001). The proviral load variations between study groups was strongly significant (ATL vs carrier P=0.0001; ATL vs HAM/TSP P= 0.0001 and HAM/TSP vs carriers P< 0.05). Conclusion : The present study demonstrated that HTLV-I proviral load was higher in ATL group in comparison with HAM/TSP and healthy carriers. Therefore, HTLV-I proviral load is a prognostic factor for development of HTLV-I associated diseases and can be used as a monitoring marker for the efficiency of therapeutic regime.

[1]  D. Nixon,et al.  Expansion in CD39+ CD4+ Immunoregulatory T Cells and Rarity of Th17 Cells in HTLV-1 Infected Patients Is Associated with Neurological Complications , 2013, PLoS neglected tropical diseases.

[2]  M. Keramati,et al.  Is there any relationship between expressions of minor blood group antigens with HTLV-I infection? , 2012, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[3]  M. Azarpazhooh,et al.  The impact of interferon-alpha treatment on clinical and immunovirological aspects of HTLV-1-associated myelopathy in northeast of Iran , 2012, Journal of Neuroimmunology.

[4]  M. Azarpazhooh,et al.  Human T-lymphotropic virus type 1 prevalence in northeastern Iran, Sabzevar: an epidemiologic-based study and phylogenetic analysis. , 2012, AIDS research and human retroviruses.

[5]  A. Muniz,et al.  Interferon Beta-1a Improves Urinary Symptoms, Reduces Proviral Load, and Modifies the Immune Response in a Patient with HAM/TSP , 2012, Case reports in neurological medicine.

[6]  K. Ogawa,et al.  CT scans of the chest in carriers of human T-cell lymphotropic virus type 1: presence of interstitial pneumonia. , 2012, Academic radiology.

[7]  Y. Yamano,et al.  Clinical Pathophysiology of Human T-Lymphotropic Virus-Type 1-Associated Myelopathy/Tropical Spastic Paraparesis , 2012, Front. Microbio..

[8]  F. Kashanchi,et al.  HTLV Tax: A Fascinating Multifunctional Co-Regulator of Viral and Cellular Pathways , 2012, Front. Microbio..

[9]  G. Mufti,et al.  Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL). , 2012, Leukemia research.

[10]  H. Rafatpanah,et al.  Design and development of a quantitative real time PCR assay for monitoring of HTLV-1 provirus in whole blood. , 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[11]  A. Duarte,et al.  Detection of human T-cell lymphotropic virus type 1 in plasma samples. , 2012, Virus research.

[12]  V. Soriano,et al.  Trends in the prevalence and distribution of HTLV-1 and HTLV-2 infections in Spain , 2012, Virology Journal.

[13]  M. Azarpazhooh,et al.  High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[14]  R. Nasr,et al.  Controversies in Targeted Therapy of Adult T Cell Leukemia/Lymphoma: ON Target or OFF Target Effects? , 2011, Viruses.

[15]  ナシュワ ハゼイン アブデルバリー リスク.  Reduced Tim-3 expression on human T-lymphotropic virus type I(HTLV-I） Tax-specific cytotoxic T lymphocytes in HTLV-I infection , 2011 .

[16]  G. Vanham,et al.  SYBR Green-based quantitation of human T-lymphotropic virus type 1 proviral load in Peruvian patients with neurological disease and asymptomatic carriers: Influence of clinical status, sex, and familial relatedness , 2006, Journal of NeuroVirology.

[17]  K. Yamaguchi,et al.  Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. , 2010, Blood.

[18]  M. Saito,et al.  Immunogenetics and the Pathological Mechanisms of Human T-Cell Leukemia VirusType 1- (HTLV-1-)Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) , 2010, Interdisciplinary perspectives on infectious diseases.

[19]  E. Wattel,et al.  Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). , 2009, Blood.

[20]  A. Duarte,et al.  Low DNA HTLV-2 proviral load among women in São Paulo City. , 2008, Virus research.

[21]  R. Gallo.  History of the discoveries of the first human retroviruses: HTLV-1 and HTLV-2 , 2005, Oncogene.

[22]  P. Korkolopoulou,et al.  Adult T-Cell Leukemia/Lymphoma (ATLL): Report of Two Fully Documented Hellenic Patients , 2004, Leukemia & lymphoma.

[23]  Società Italiana di Emaferesi.  Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis , 2001 .

[24]  B. Bain,et al.  Prospective study of HTLV-I infection in an initially asymptomatic cohort. , 1999, Journal of acquired immune deficiency syndromes.

[25]  M. Tomonaga,et al.  Diversity of leukaemic cell morphology in ATL correlates with prognostic factors, aberrant immunophenotype and defective HTLV‐1 genotype , 1999, British journal of haematology.

[26]  S. Izumo,et al.  Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. , 1999, Journal of neurovirology.

[27]  S. Izumo,et al.  Analysis Of Htlv-I Proviral Load In 202 Ham/Tsp Patients And 243 Asymptomatic Htlv-I Carriers: High Proviral Load Strongly Predisposes To Ham/Tsp , 1998 .

[28]  Shinsuke Suzuki,et al.  Treatment for adult T-cell leukemia , 1997, Cancer Chemotherapy and Pharmacology.

[29]  M. Greaves,et al.  HTLV-I positive adult T-cell leukaemia/lymphoma (ATLL) in Chile. , 1994, Leukemia.